Cytochrome P450 genes expression in human prostate cancer.

Mol Genet Metab Rep

Institute of Molecular Biology and Genetics, Department of Molecular Oncogenetics, National Academy of Sciences of Ukraine, 150 Zabolotnogo Street, Kyiv 03143, Ukraine.

Published: March 2024

CYP-dependent metabolites play a critical role in regulating the cell cycle, as well as the proliferative, invasive, and migratory activity of cancer cells. We conducted a study to analyze the relative gene expression of various () in 41 pairs of prostate samples (tumor and conventional normal tissues) using qPCR. Our analysis determined significant individual variability in the expression levels of all studied both in the tumor and in conventionally normal groups. However, when we performed a paired test between the tumor and normal groups, we found no significant difference in the expression of the studied genes. We did observe a tendency to increase the level of expression in the tumor group. We also did not find any significant difference between the levels of the studied in the tumor and conventional normal groups at different stages of prostate cancer and pathomorphological indicators. Correlation analysis revealed the presence of a positive relationship between the expressions of some cholesterol-metabolizing genes, as well as between genes responsible for vitamin D biosynthesis and cholesterol biosynthesis. We observed significant correlative relationships between the expression of and some prostate cancer-related genes (). Therefore, the expression of is not directly associated with prostate cancer but is largely determined by genetic, epigenetic factors, as well as endogenous substrates and xenobiotics. The significant correlative relationship between and genes associated with cancer may indicate common regulatory pathways that may have a synergistic effect on the tumor, ensuring the survival of cancer cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926225PMC
http://dx.doi.org/10.1016/j.ymgmr.2024.101049DOI Listing

Publication Analysis

Top Keywords

prostate cancer
12
normal groups
12
genes expression
8
cancer cells
8
tumor conventional
8
conventional normal
8
levels studied
8
studied tumor
8
expression
7
genes
6

Similar Publications

Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid.

View Article and Find Full Text PDF

Background: In TALAPRO-2, the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor-signaling inhibitor enzalutamide improved radiographic progression-free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51-0.

View Article and Find Full Text PDF

Advancements in pseudouridine modifying enzyme and cancer.

Front Cell Dev Biol

December 2024

Department of Oncology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.

Pseudouridine (Ψ) is a post-transcriptional modifier of RNA, often referred to as the 'fifth nucleotide' owing to its regulatory role in various biological functions as well as because of its significant involvement in the pathogenesis of human cancer. In recent years, research has revealed various Ψ modifications in different RNA types, including messenger RNA, transfer RNA, ribosomal RNA, small nuclear RNA, and long noncoding RNA. Pseudouridylation can significantly alter RNA structure and thermodynamic stability, as the Ψ-adenine (A) base pair is more stable than the typical uridine (U)-A base pair is due to its structural similarity to adenine.

View Article and Find Full Text PDF

Silencing of STEAP3 suppresses cervical cancer cell proliferation and migration via JAK/STAT3 signaling pathway.

Cancer Metab

December 2024

Department of Obstetrics and Gynecology, First Affiliated Hospital, Shihezi University, Shihezi, China.

Article Synopsis
  • STEAP3 is a critical protein associated with cervical cancer (CC) progression, showing strong expression in CC tissues and linked to poor patient prognosis.
  • The study employed various methods, such as immunohistochemistry and RNA sequencing, to investigate STEAP3's role, revealing that lower methylation levels of STEAP3 are connected to worse outcomes.
  • Knockdown of STEAP3 in CC cells reduced their growth and invasion abilities while enhancing drug sensitivity, suggesting STEAP3 drives cancer cell activity through the activation of the JAK/STAT3 signaling pathway.
View Article and Find Full Text PDF

Background: To assess the clinical utility of PCA3 in the diagnostic accuracy, the correlation between PCA3 and biopsy or pathological characteristics and the performance of PCA3 to reduce the unnecessary biopsies in Chinese population.

Methods: A prospective study including patients with indication of prostate biopsies from 4 centers was conducted. All patients underwent PCA3 urine tests and prostate biopsies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!